Antidiabetic potential of Selenium nanoparticles and plasma-rich platelets in diabetic mice

Diabetes mellitus is a widespread endocrine disorder, which is categorized as the fourth leading cause of global mortality. Allopathic medicine has yet to provide a satisfactory cure for this condition. Consequently, there is an urgent demand for innovative antidiabetic treatment approaches with enhanced management and minimum side effects and costs. The study investigated the synergistic antidiabetic potential of combining selenium nanoparticles (Se NPs) and plasma-rich platelets (PRP) in diabetic mice. Antidiabetic activity of the proposed combination (Se NPs and PRP) was evaluated from histopathological and biochemical perspectives. The experiment involved alloxan monohydrate induced diabetic mouse model. In the in vivo study, several biochemical parameters for assessing the antidiabetic effect of the novel combination of (Se NPs and PRP) were performed such as blood glucose levels, body weight, lipid profiles, and liver damage markers (AST and ALT). Scavenging antioxidant activity was assessed by evaluation levels of hepatic and renal GSH, MDA, SOD, and CAT activities. Complete histopathological examinations of vital internal organs were carried out. Results revealed that combining Se NPs and PRP presents a novel approach for better diabetes management and reduced complications associated with the disease. These findings have therapeutic implications for managing diabetes mellitus.